一种新型非肽类直接凝血酶抑制药——Praxbind的临床应用

Clinical application of Praxbind,an intravenous selective inhibitor

目的 Praxbind是一种静脉注射的达比加群特异性逆转药,其主要用于患者需要逆转达比加群的抗凝剂效应治疗时使用。本文从Praxbind的作用机制、药代动力学、药效学、临床研究试验、药物安全性、有效性以及特殊人群用药等方面进行阐述,为以后临床用药提供参考。

Praxbind （idarucizumab） is an intravenous selective inhibitor of dabigatran, which is mainly used for the patients who need to reverse the anticoagulant effect. In this paper, the mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials, drug safety, efficacy of Praxbind as well as the special groups of drugs are described, in order to guide the rational use of drugs.